NCT06420739

Brief Summary

The primary goal of this study is to evaluate the incidence of "full stomach" in fasting elective surgical patients on Semaglutide medication. The other goals are to study the impact of the time interval since the last dose of the medication on the incidence of full stomach and to develop evidence-based recommendations for the perioperative management of these patients.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 25, 2024

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

April 10, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 20, 2024

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2025

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2026

Completed
Last Updated

November 20, 2025

Status Verified

October 1, 2025

Enrollment Period

1.7 years

First QC Date

April 10, 2024

Last Update Submit

November 17, 2025

Conditions

Keywords

Gastric UltrasoundFastingSemaglutideElective surgery

Outcome Measures

Primary Outcomes (1)

  • Incidence of full stomach.

    Frequency of full stomach in patients taking semaglutide and fasting before surgery. Analysis of the primary outcome will be based on a chi-square analysis.

    Pre-Surgical fasting duration per guideline

Secondary Outcomes (2)

  • Any changes in anesthetic management from the a priori plan following the result of the gastric ultrasound examination.

    Pre-operative anesthesia management plan

  • Impact of age, sex and the time since the last dose of Semaglutide, on the incidence of "full stomach".

    Pre-Surgical fasting duration per guideline

Interventions

Gastric UltrasoundDIAGNOSTIC_TEST

Bedside Gastric Ultrasound to determine the volume and nature of gastric content in patients before their surgery.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A cohort of 100 patients undergoing elective surgery while under treatment with Semaglutide for either diabetes or for losing weight.

You may qualify if:

  • Patients scheduled for elective surgery at Toronto Western Hospital
  • Aged ≥ 18 years of age
  • American Society of Anaesthesia physical status classification I to III
  • Patients being treated with Semaglutide for at least 1 month

You may not qualify if:

  • Current pregnancy evidenced by positive urinary pregnancy test
  • Previous surgery of the upper gastrointestinal tract

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Toronto Western Hospital

Toronto, Ontario, M5T 2S8, Canada

Location

MeSH Terms

Conditions

Fasting

Condition Hierarchy (Ancestors)

Feeding BehaviorBehavior

Study Officials

  • Anahi Perlas

    Investigator-Sponsor

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 10, 2024

First Posted

May 20, 2024

Study Start

March 25, 2024

Primary Completion

November 30, 2025

Study Completion

March 31, 2026

Last Updated

November 20, 2025

Record last verified: 2025-10

Data Sharing

IPD Sharing
Will not share

Locations